What changed
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025. Once a drug is no longer in shortage, pharmacies generally cannot make copies that are essentially the same as the approved product, after short transition periods that have now ended. Legal challenges by compounders were pending as of October 2026.
FDA warnings
Compounded drugs are not FDA-approved, so they have not been reviewed for safety, effectiveness or quality. The FDA has sent warning letters to companies marketing compounded GLP-1s with misleading claims, such as implying they are the same as brand-name drugs, and has received reports of dosing errors with compounded products.
If you are considering a GLP-1
- Talk to a licensed clinician about whether a GLP-1 is right for you.
- Be wary of sellers that do not require a prescription or medical history.
- Check insurance coverage and manufacturers’ savings programs for approved drugs.
- On Medicare? See negotiated prices for semaglutide.
- Choose med spas carefully: see med spa safety.
General information, not medical, legal or insurance advice. This post reflects the position on the date shown. Check the official sources below for the latest rules.
Last updated: 15 October 2026
